Related Experiment Video
Updated: Mar 30, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
Antimitotic drugs in the treatment of cancer
Rustelle Janse van Vuuren1, Michelle H Visagie2, Anne E Theron1
1Department of Physiology, University of Pretoria, Private Bag x 323, Arcadia, 0007, South Africa.
Abstract:
Cancer is a complex disease since it is adaptive in such a way that it can promote proliferation and invasion by means of an overactive cell cycle and in turn cellular division which is targeted by antimitotic drugs that are highly validated chemotherapy agents. However, antimitotic drug cytotoxicity to non-tumorigenic cells and multiple cancer resistance developed in response to drugs such as taxanes and vinca alkaloids are obstacles faced in both the clinical and basic research field to date. In this review, the classes of antimitotic compounds, their mechanisms of action and cancer cell resistance to chemotherapy and other limitations of current antimitotic compounds are highlighted, as well as the potential of novel 17-β estradiol analogs as cancer treatment.
More Related Videos
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
12:28Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
Published on: January 11, 2019
Related Concept Videos
Drugs that Stabilize Microtubules
Drugs that Destabilize Microtubules
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies
Inhibition of Cdk Activity
Inhibition of CDK Activity